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The human rhinoviruses (HRVs) are the single most important cause of common colds. The widespread nature of this affliction, the economic
consequences, and the well-known impracticality of vaccine development due to the large number of HRV serotypes (>100) have justified the
search for chemotherapeutic agents. The interest in the application of quantitative structure–activity relationships has steadily increased in recent
decades and we hope it may be useful in the search for anti-HRV agents. In the present paper, we have discussed the inhibition of various six
compound series against HRV-1A, -1B, -2, -9, -14, -21, -22, -25, -64, and -89 by the formulation of a total number of 14 QSAR. Hydrophobicity is
found to be one of the most important determinants of activity. Parabolic correlation with the hydrophobic parameter (Eq. (7)) is an encouraging
example, where the optimal hydrophobicity is well defined. We believe that this may be the predictive model to narrow the synthetic challenges in
order to yield very specific HRV-2 inhibitors. On the basis of this model, we have predicted eleven compounds (I-1 to I-11) that may be the next
synthetic target. The proposed molecules (I-1 to I-11) also fulfill the conditions of Lipinski's “rule of five”.
© 2006 Elsevier Inc. All rights reserved.Keywords: Human rhinoviruses (HRVs); QSAR; Hydrophobicity; Molar refractivity; Lipinski's “rule of five”Introduction
Human rhinoviruses (HRVs) are a genus of the picornavirus
family and are the major causative agent of common colds,
producing the classic symptoms of a runny nose, blocked
sinuses, headache, fever and cough. Human rhinovirus infec-
tions have been associated with the development of otitis media,
pneumonia and sinusitis in children and also in more serious
diseases in both the upper and lower respiratory tracts (Couch,
2001). These infections can be more serious in patients
suffering from chronic respiratory diseases, triggering acute
exacerbations of asthma, emphysema and chronic obstructive
pulmonary disease (COPD). HRV infections may also be
associated with substantial morbidity in the elderly. It seems to
most often begin with a child and can be spread from one person
to another. The most important route of transmission is through
hand to hand contact. Optimum environment for HRV
replication is 33–35 °C. It does not replicate efficiently at
body temperature. This may explain why HRV replicates well in
the nasal passages and upper respiratory tract but less well in the⁎ Corresponding author. Fax: +1 909 607 7726.
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doi:10.1016/j.virol.2006.09.012lower respiratory tract. HRV infections are also considered to be
associated with an enormous economic burden both in lost
productivity and in expenditure for treatment. It is estimated that
each year the common cold is responsible for about 20 million
missed work days, 22 million missed school days, and 27
million physician visits in the United States alone (Adams et al.,
1999). In addition, billions of dollars per year are spent in the
United States on prescription and over-the-counter medicines
associated with treatments for the common cold (Bertino,
2002). Thus, prevention or treatment of HRV infections to avoid
these complications would have an enormous societal impact
with regard to both morbidity and economic cost.
The HRV surface is composed of four proteins VP1, VP2,
VP3, and VP4 that are arranged in a symmetrical array repeated
60 times to form the capsid that surrounds the positive-strand
RNA genome. Upon cellular infection, the freed positive strand
mRNA genome is translated into one large pre-protein that
requires processing to release the active protein components. In
an effort similar to those of herpes, hepatitis C, and HIV, mole-
cules have been designed to inhibit the function of the HRV
proteases. These proteases are required for the efficient HRV
replication, which are responsible for the cleavage of poly-
protein precursor. Since 3C protease is responsible for the
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been tested enzymatically. On the other hand, more than 100
HRV serotypes (containing the subtype HRV1A and HRV1B as
one strain) are known to date and are divided into two groups by
their receptor usage. The HRV serotypes, termed the major
group, use intracellular the adhesion molecule-1 (ICAM-1) as
their cellular receptor. The reminder of the HRV serotypes
composes the minor group, and use members of the low-density-
lipoprotein receptor (LDLR) (Charles et al., 2004). By phylo-
genetic analysis of capsid protein VP4/VP2 coding sequences of
all HRV prototype strains, 74 HRV serotypes, including all the
minor receptor groups, were classified as HRV species A, while
the 25 remaining serotypes from the HRV species B (Savolainen
et al., 2002). Thus the recent interest has been directed at
discovering HRV 3C protease inhibitors with antiviral activity
against the spectrum of known rhinovirus serotypes.
The HRV coat protein inhibitors act as capsid-binding anti-
viral agents that block the uncoating of the viral particles and/or
inhibit cell attachment. Their binding site is located within a
hydrophobic pocket situated at the bottom of a depression, a so-
called canyon, on the capsid surface. In the absence of an
inhibitor, this pocket may be empty or occupied by a pocket
factor, a lipid or fatty acid. Structural conservation in this region
among the different serotypes permits the development of board
spectrum anti-HRV agents (Steindl et al., 2005). The serotypic
variation of HRVs suggests that antiviral spectrum and potency
must be considered equally important in drug design. Structural
information is also useful but it can be generalized to apply to
different HRV serotypes. This has considerably handicapped the
application of structural information to the problem—while
crystallography, molecular modeling, QSAR and dynamics may
be useful in improving potency of antiviral drugs against specific
HRVs.
In a recent study, HeLa and 16HBE14o− bronchial epithelium
cells infected with human rhinovirus serotype 14 (HRV14) were
found to exhibit apoptotic morphological alterations, such as cell
contraction and nuclear condensation. These events coincided
with high-molecular weight DNA fragmentation, activation of
caspase-9, caspase-3, and poly(ADP-ribose) polymerase clea-
vage. The caspase activation was preceded by cytochrome c
translocation from the mitochondria to the cytoplasm, which
indicated that apoptosis caused byHRV14 infection was triggered
predominantly via the mitochondrial pathway. Apoptosis did not
affect HRV14 replication but it facilitated the release of newly
formed virus from cells (Deszcz et al., 2005).
The present treatment options for HRV infections are
unsatisfactory. There are ongoing attempts to develop antiviral
for HRV infections. Pleconaril, an antiviral with good activity
against the rhinoviruses, has only modest effects on the symp-
toms of the common cold in healthy adults (Hayden et al., 2003).
The effect of pleconaril on the morbidity associated with
rhinovirus infections in high-risk patients has not yet been
carefully evaluated. Pfizer's ruprintrivir (AG-7088) has demon-
strated the most potent anti-HRVactivity. In vitro, this molecule
inhibited the replication of 48 HRV serotypes and looks
promising in clinical trials. Treatment of HRV-infected patients
with ruprintrivir reduced symptom scores 33% relative toplacebo, indicating that this drug may be useful. The other
compounds that demonstrated potent anti-HRV activities are
enviroxime, 2-furylmercury chloride, disoxaril, and pirodavir
etc. (Charles et al., 2004).Many people are convinced that taking
large quantities of vitamin C will prevent colds or relieve
symptoms. It may reduce the severity or duration of symptoms,
but there is no clear evidence for curative activity. Taking large
amounts of vitamin C for a long period of time may cause severe
diarrhea, a particular danger for elderly people and small
children.
In the present paper, we would like to demonstrate the QSAR
(quantitative structure–activity relationship) studies on various
sets of compounds with respect to their anti-HRV activities to
understand the chemical–biological interactions. In the past 44
years, the use of QSAR (one of the well-developed areas in
computational chemistry), since the advent of this methodology
(Hansch et al., 1962), has become increasingly helpful in
understanding many aspects of chemical–biological interac-
tions in drug and pesticide research, as well as in the areas of
toxicology. This method is useful in elucidating the mechanisms
of chemical–biological interaction in various biomolecules,
particularly enzymes, membranes, organelles and cells, as well
as in human (Hansch and Leo, 1995; Selassie et al., 2002a;
Verma et al., 2005b). It has also been utilized for the evaluation
of absorption, distribution, metabolism and excretion (ADME)
phenomena in many organisms and whole animal studies
(Hansch et al., 2004). The QSAR approach employs extra-
thermodynamically derived and computational-based descrip-
tors to correlate biological activity in isolated receptors, cellular
systems and in vivo. Three standard molecular descriptors
routinely used in QSAR analysis: electronic, hydrophobic and
steric, including topological indices, are invaluable in helping to
delineate a large number of receptor–ligand interactions that are
critical to biological processes (Hansch and Leo, 1995). The
quality of a QSAR model depends strictly on the type and
quality of the data, and not on the hypotheses, and is valid only
for the compound structures analogs to those used to build the
model. QSAR models can stand alone to augment other
graphical approaches or can be examined in tandem with
equations of a similar mechanistic genre to establish their
authenticity and reliability (Selassie et al., 2002b). Potential use
of QSAR models for screening of chemical databases or virtual
libraries before their synthesis appears equally attractive to
chemical manufacturers, pharmaceutical companies and gov-
ernment agencies.
Results and discussion
Human rhinovirus 1A (HRV-1A)
Inhibition of HRV-1A by 3-X-5-Y-phenylisoxazoles (I) (Diana
et al., 1989) (Table 1)).
A QSAR study revealed that the mean MIC against five
rhinovirus serotypes correlated well with hydrophobicity. We
considered the MIC values of phenylisoxazoles (I) against
individual rhinovirus serotypes to formulate a number of QSAR
models. For this set of compounds the activity was expressed as
Table 1
Biological and physicochemical parameters used to derive QSAR Eqs. (1), (7) and (9) for the inhibition of HRV-1A, HRV-2, and HRV-14, respectively by 3-X-5-Y-
phenylisoxazoles (I)
No. X Y Log1/MIC (Eq. (1)) Log1/MIC (Eq. (7)) Log1/MIC (Eq. (9)) Clog P MgVol
Obsd. Pred. Δ Obsd. Pred. Δ Obsd. Pred. Δ
1 H H 5.15 5.13 0.02 5.96 a 6.72 −0.76 6.15 6.08 0.07 3.91 2.44
2 CH3 CH3 5.70 5.65 0.05 7.70 7.50 0.20 5.62 5.74 −0.12 4.91 2.72
3 Cl Cl 5.60 5.73 −0.13 7.70 7.42 0.28 5.92 5.90 0.02 5.07 2.68
4 Br Br 5.92 5.89 0.03 7.00 7.13 −0.13 5.85 5.75 0.10 5.37 2.79
5 F F 4.97 5.17 −0.20 6.89 6.85 0.04 5.96 6.01 −0.05 3.99 2.47
6 Cl CF3 5.85 6.00 −0.15 6.70 6.82 −0.12 5.82 5.91 −0.09 5.57 2.75
7 Cl Br 6.00 5.81 0.19 7.40 7.30 0.10 6.00 5.82 0.18 5.22 2.73
8 NO2 Br 5.41 5.36 0.05 7.00 7.33 −0.33 5.89 b 5.35 0.54 4.36 2.79
9 NO2 Cl 5.48 5.28 0.20 7.15 7.18 −0.03 6.05 b 5.43 0.62 4.21 2.73
10 Cl CH3 5.68 5.72 −0.04 7.40 7.44 −0.04 5.72 5.84 −0.12 5.04 2.70
11 OCH3 OCH3 4.78 4.81 −0.03 5.21 5.15 0.06 4.80 4.80 0.00 3.30 2.84
a Not included in the derivation of QSAR (7).
b Not included in the derivation of QSAR (9).
154 R.P. Verma, C. Hansch / Virology 359 (2007) 152–161MIC in molar concentration. From the data in Table 1, Eq. (1)
was derived.
log1=MIC ¼ 0:52ðF0:13ÞClogP þ 3:10ðF0:62Þ ð1Þ
n=11, r2=0.898, s=0.133, q2=0.853, Q=7.128, F=
79.235. Range in log 1/MIC=4.78 to 6.00.
Correlation matrix for Clog P vs. σm, CMR, MW, MgVol,
and NVE: r2 <0.5.
Hydrophobicity is found to be the single most important
parameter for this dataset, which shows that at all the parts where
substituents have been entered, hydrophobic contacts have beenTable 2
Biological and physicochemical parameters used to derive QSAR equation (2), (8), a
dihydro-2-phenyl-2H-pyrano[2,3-b]pyridines (II)
No. X Y log 1/ID50 (Eq. (2)) log 1/ID
Obsd. Pred. Δ Obsd.
1 Cl 4-Cl 7.15 7.06 0.09 6.19
2 Br H 6.39 6.73 −0.34 5.32
3 Br 3,4-Cl2 7.52 7.49 0.03 6.66
4 Cl 3,4-Cl2 7.22 7.40 −0.18 6.54
5 Br 4-CH3 7.15 7.02 0.13 6.41
6 Br 4-Cl 7.52 7.14 0.38 7.52 b
7 SO2CH3 3,4-Cl2 6.33 6.33 0.00 6.85
8 SOCH3 3,4-Cl2 6.59 6.38 0.21 7.52
9 SO2CH3 4-Cl 5.85 5.99 −0.14 5.85 b
10 H 3,4-Cl2 7.15 6.97 0.18 5.66
11 S(CH2)3CH3 3,4-Cl2 5.55
c 8.22 −2.67 5.20
12 SCH3 3,4-Cl2 6.92 7.29 −0.37 6.82
a Not included in the derivation of QSAR (13).
b Not included in the derivation of QSAR (8).
c Not included in the derivation of QSAR (2).made. The linear Clog P model suggests that the highly hydro-
phobic molecules will be more active. Eq. (1) explains 89.8% of
the variance in log 1/MIC. No term appears forXand Y sub-
stituents. σm is the sum of the σ values ofXand Y substituents.
Inhibition of HRV-1A by 3,4-dihydro-2-phenyl-2H-pyrano
[2,3-b]pyridines (II) (Bargar et al., 1986) (Table 2).
From the data in Table 2, Eq. (2) was derived. ID50 is the molar
concentration of test compound required to reduce virus-induced
plaque formation in HeLa cell culture to 50% of control.
log1=ID50 ¼ 0:58ðF0:22ÞClogP þ 4:24ðF0:99Þ ð2Þnd (13) for the inhibition of HRV-1A, HRV-9, and HRV- 64, respectively by 3,4-
50 (Eq. (8)) log 1/ID50 (Eq. (13)) Clog P CMR
Pred. Δ Obsd. Pred. Δ
5.85 0.34 6.96 a 6.24 0.72 4.82 7.34
5.41 −0.09 5.45 5.65 −0.20 4.26 7.13
6.88 −0.22 7.22 7.64 −0.42 5.57 8.12
6.62 −0.08 7.52 7.27 0.25 5.42 7.83
6.31 0.10 6.64 6.84 −0.20 4.76 7.60
6.35 1.17 7.52 6.90 0.62 4.97 7.62
7.00 −0.15 8.00 7.87 0.13 3.58 8.67
7.01 0.51 8.05 7.87 0.18 3.67 8.64
6.93 −1.08 6.60 a 7.70 −1.10 2.99 8.18
5.85 −0.19 6.19 6.24 −0.05 4.67 7.34
5.22 −0.02 5.86 5.83 0.03 6.82 10.00
7.02 −0.20 7.52 7.88 −0.36 5.23 8.61
Table 4
Biological, physicochemical, and structural parameters used to derive QSAR
Eq. (4) for the inhibition of HRV-1B by 2-X-6-(dimethylamino)-9-(Y-benzyl)-
9H-purines (IV)
No. X Y Log1/IC50 (Eq. (4)) πY−3 B1Y−4 IX
Obsd. Pred. Δ
1 H 3-NH2 4.30 3.94 0.36 −1.23 1.00 0
2 H H 4.48 4.44 0.04 0.00 1.00 0
3 H 4-CH3 5.07 4.99 0.07 0.00 1.52 0
4 H 4-OCH3 4.42 4.81 −0.39 0.00 1.35 0
5 H 4-OCH2C6H5 4.47 4.81 −0.34 0.00 1.35 0
6 H 3-CF3 4.71 4.80 −0.09 0.88 1.00 0
7 H 3-I 5.17 4.90 0.28 1.12 1.00 0
8 H 3-Br 4.84 4.79 0.05 0.86 1.00 0
9 H 3-Cl 4.52 4.73 −0.21 0.71 1.00 0
10 H 3,5-Cl2 5.34 4.73 0.61 0.71 1.00 0
11 H 3,4-Cl2 5.60 5.58 0.02 0.71 1.80 0
12 H 3-CH3 4.49 4.67 −0.17 0.56 1.00 0
13 H 3-F 4.64 4.50 0.14 0.14 1.00 0
14 H 3-OCH3 4.30 4.43 −0.13 −0.02 1.00 0
15 H 3-OCH2C6H5 4.89 5.12 −0.23 1.66 1.00 0
16 Cl H 6.09 5.95 0.14 0.00 1.00 1
17 Cl 4-Cl 6.92 6.80 0.12 0.00 1.80 1
18 Cl 4-CH3 7.10 6.50 0.60 0.00 1.52 1
19 Cl 4-C2H5 7.10 6.50 0.60 0.00 1.52 1
20 Cl 4-CH(CH3)2 7.15 6.90 0.25 0.00 1.90 1
21 Cl C(CH3)3 6.36
a 7.65 −1.29 0.00 2.60 1
22 Cl 4-OCH3 6.15 6.32 −0.17 0.00 1.35 1
23 Cl 4-NO2 6.29 6.69 −0.40 0.00 1.70 1
24 Cl 4-NH2 6.52 6.32 0.20 0.00 1.35 1
25 Cl 3-I 6.44 6.41 0.04 1.12 1.00 1
26 Cl 3-Cl 6.23 6.24 −0.01 0.71 1.00 1
27 Cl 3,4-Cl2 6.49 7.09 −0.59 0.71 1.80 1
28 Cl 3-CH3 6.22 6.18 0.04 0.56 1.00 1
29 Cl 3-OCH3 5.70 5.94 −0.24 −0.02 1.00 1
30 Cl 3-NH2 4.89 5.45 −0.56 −1.23 1.00 1
a Not included in the derivation of QSAR (4).
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37.392. Range in log 1/ID50=4.78 to 6.00.
Outlier:X=S(CH2)3CH3, Y=3,4-Cl2.
Correlation matrix for Clog P vs. σX, MRX, CMR, MgVol,
and NVE: r2 <0.5.
Again we obtained a positive hydrophobic term (Clog P).
The positive coefficient of Clog P indicates that the increase in
hydrophobicity of the molecules would be favorable to their
activity against HRV-1A as similar to QSAR 1. One compound
in Table 2 for the development of QSAR 2 was deemed to be
outlier on the basis of their deviations (>2s). MRX is the molar
refractivity of the X substituents while CMR is the molar
refractivity of the whole molecules.
Human rhinovirus 1B (HRV-1B)
Inhibition of HRV-1B by 2-X-6-(dimethylamino)-9-(4-methyl-
benzyl)-9H-purines (III) (Kelley et al., 1989) (Table 3).
Kelley et al. synthesized a series of 2-X-6-(dimethylamino)-
9-(4-methylbenzyl)-9H-purines (III) and tested their antirhino-
virus activity, and suggested that the optimum antirhinovirus
serotype 1B activity is associated with 9-benzylpurines that
contained a C-2 lipophilic, electron-withdrawing substituent.
From the data in Table 3, we derived Eq. (3).
log1=IC50 ¼ 1:11ðF0:26ÞpX þ 5:78ðF0:22Þ ð3Þ
n=10, r2=0.925, s=0.298, q2=0.898, Q=3.228, F=98.667.
Range in log 1/IC50=4.51 to 7.52.
Outlier: X=C2H5.Table 3
Biological and physicochemical parameters used to derive QSAR Eq. (3) for the
inhibition of HRV-1B by 2-X-6-(dimethylamino)-9-(4-methylbenzyl)-9H-
purines (III)
No. X Log1/IC50 (Eq. (3)) πX
Obsd. Pred. Δ
1 Cl 7.10 6.93 0.17 1.04
2 H 5.07 5.77 −0.70 0.00
3 CF3 7.52 7.43 0.09 1.49
4 CH3 6.10 6.33 −0.23 0.50
5 C2H5 5.64
a 6.82 −1.18 0.94
6 F 6.47 6.30 0.17 0.47
7 NH2 4.51 4.34 0.17 −1.29
8 NHCH3 5.33 5.11 0.22 −0.60
9 N(CH3)2 5.96 5.89 0.07 0.10
10 SCH3 6.47 6.39 0.08 0.55
11 SO2CH3 4.60 4.64 −0.04 −1.02
a Not included in the derivation of QSAR (3).Correlation matrix for πX vs. MRX, Clog P, CMR, MgVol,
and NVE: r2 <0.5.
πX is the hydrophobic parameter for X substituents. The
positive contribution of πX suggests that higher hydrophobic X
substituents will increase the activity against rhinovirus
serotype 1B. IC50 is the 50% inhibitory molar concentration.
Inhibition of HRV-1B by 2-X-6-(dimethylamino)-9-(Y-
benzyl)-9H-purines (IV) (Kelley et al., 1988) (Table 4).
Kelley et al. also synthesized a series of purines using
different substituents at the benzyl ring that is 2-X-6-(dimethy-
lamino)-9-(Y-benzyl)-9H-purines (IV) and tested their antirhi-
novirus activity against HRV-1B. We derived Eq. (4) from the
data in Table 4.
Table 6
Biological and physicochemical parameters used to derive QSAR Eq. (6) for the
inhibition of HRV-2 by pyridazinylpiperidinyl derivatives (IV)
No. X Y log1/EC50 (Eq. (6)) Clog
P
Obsd. Pred. Δ
1 O OC2H5 7.35 7.32 0.03 4.44
2 O SC2H5 8.40
a 7.15 1.25 4.78
3 S OC2H5 6.98 6.99 −0.01 5.12
4 S OCH2CH2CH3 6.78 6.73 0.05 5.65
5 S SC2H5 6.78 6.82 −0.04 5.46
6 NCH3 SC2H5 7.07 7.09 −0.03 4.90
a Not included in the derivation of QSAR (6).
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þ 1:51ðF0:28ÞIX þ 3:38ðF0:54Þ ð4Þ
n=29, r2=0.893, s=0.334, q2=0.848, Q=2.829, F=69.548.
Range in log 1/IC50=4.30 to 7.15.
Outlier: X=Cl, Y=C(CH3)3.
Correlation matrix for πY−3 vs. LY−4, B1Y−4, B5Y−4, Clog P,
CMR, MgVol, NVE, and IX: r
2 <0.5.
πY−3 is the hydrophobic parameter for Y substituents at
position-3. The positive contribution of πY−3 suggests that
highly hydrophobic substituents at position-3 in the phenyl ring
will increase the activity. B1Y− 4 is the sterimol parameter for Y
substituents at position-4, which is the measure of minimum
width of those substituents and suggests a positive effect on the
inhibition. Indicator variable IX=1 for the presence of X=Cl
and 0 for X=H. The positive coefficient of the indicator variable
(IX) indicates that the presence of Cl group at X-position will
improve the activity as observed in QSAR 4.
Human rhinovirus 2 (HRV-2)
Inhibition of HRV-2 by 2-(X-phenoxy)-5-nitrobenzonitriles
(V). (Markley et al., 1986) (Table 5).
From the data in Table 5, QSAR 5 was derived.Table 5
Biological and physicochemical parameters used to derive QSAR Eq. (5) for the
inhibition of HRV-2 by 2-(X-phenoxy)-5-nitrobenzonitriles (V)
No. X log1/MIC50 (Eq. (5)) Clog P
Obsd. Pred. Δ
1 3,4-Cl2 6.59 6.33 0.26 4.72
2 2,4-Cl2 6.28 6.25 0.03 4.61
3 3,5-Cl2 5.09
a 6.43 −1.34 4.84
4 2,6-Cl2 6.28 6.07 0.21 4.38
5 2,3-Cl2 6.59 6.15 0.44 4.49
6 2,5-Cl2 6.28 6.25 0.03 4.61
7 4-Cl 5.55 5.87 −0.32 4.13
8 3-Cl 6.24 5.87 0.37 4.13
9 2-Cl 5.35 5.69 −0.34 3.90
10 4-Br 5.42 a 5.98 −0.56 4.28
11 2-Br 6.03 5.80 0.23 4.05
12 4-OCH3 4.94 5.24 −0.30 3.34
13 3-OCH3 5.03 5.24 −0.21 3.34
14 2-OCH3 5.04 4.97 0.07 2.99
15 H 5.27 5.31 −0.04 3.42
16 4-CH3 5.29 5.70 −0.41 3.92
17 4-CN 5.03 4.86 0.17 2.85
18 4-CF3 6.00 6.00 0.00 4.30
19 3-CF3 5.70 6.00 −0.30 4.30
20 2-CF3 5.41
a 6.00 −0.59 4.30
21 3,4-(OCH3)2 4.68 5.04 −0.36 3.07
22 4-COCH3 4.95 4.87 0.08 2.86
23 4-SCH3 4.66
a 5.75 −1.09 3.98
24 4-SO2CH3 4.41 4.02 0.39 1.78
a Not included in the derivation of QSAR (5).log1=MIC50 ¼ 0:79ðF0:17ÞClogP þ 2:63ðF0:67Þ ð5Þ
n=20, r2=0.833, s=0.280, q2=0.776, Q=3.261, F=89.784.
Range in log 1/MIC50=4.41 to 6.59.
Outliers: X=3,5-Cl2; 4-Br; 2-CF3; 4-SCH3.
Correlation matrix for Clog P vs. πX−2, πX−3, MRX−2, MRX−3,
MRX−4, σ, σ
+, σ-, CMR, MgVol, and NVE: r2<0.5.
Hydrophobicity is found to be one of the single most
important parameters for this dataset. The linear Clog P model
suggests that the highly hydrophobic molecules will be more
active. MIC50 is the minimum inhibitory concentration: the
molar concentration of compounds (V) to reduce the viral
cytopathic effect by 50% compared to control.
Inhibition of HRV-2 by pyridazinylpiperidinyl derivatives
(VI). (Brown et al., 2005) (Table 6).
The activity of test compounds (EC50) was expressed in
molar concentration to cause 50% inhibition of HRV-2. We
derived Eq. (6) from the data in Table 6.
log1=EC50 ¼ 0:49ðF0:14ÞClogP þ 9:47ðF0:74Þ ð6Þ
n=5, r2=0.975, s=0.043, q2=0.895, Q=22.953, F=117.000.
Range in log 1/EC50=6.78 to 8.40.
Outlier: X=O, Y=SC2H5.
Correlation matrix for Clog P vs. CMR, MgVol, and NVE:
r2 <0.5.
QSAR 6 is an excellent correlation between the inhibition
potencies and the hydrophobicity of the compounds. The
negative coefficient of Clog P indicates that the increase in
hydrophobicity of the molecules would be detrimental to
their activity. An interesting observation was made by the
comparison of compounds 2, 5, and 6 illustrated the
influence of a heteroatom in the X position. As compared
to an oxygen atom (compound 2, which is an outlier), the
Table 7
Predicted log 1/MIC for the proposed molecules (I-1 to I-11) against HRV-2
along with Clog P, molecular weight, and the number of hydrogen bond
acceptors and donors (conditions of Lipinski's “rule of five”)
No. X Y Log1/MIC predicted
from Eq. (7)
Clog P Mol. Wt. HBA HBD
I-1 CH3 F 7.40 4.50 346.44 5 0
I-2 CH3 NO2 7.10 4.18 373.45 8 0
I-3 CH3 OCH3 7.06 4.15 358.48 6 0
I-4 CH3 H 7.34 4.41 328.45 5 0
I-5 OCH3 F 6.17 3.67 362.44 6 0
I-6 OCH3 Cl 7.13 4.21 378.89 6 0
I-7 OCH3 Br 7.29 4.36 423.34 6 0
I-8 OCH3 CF3 7.49 4.74 412.45 6 0
I-9 C2H5 NO2 7.48 4.71 387.48 8 0
I-10 NO2 F 6.17 3.67 377.41 8 0
I-11 NO2 H 6.19 3.68 359.42 8 0
HBA=number of hydrogen bond acceptors (expressed as the sum of Ns and Os).
HBD=number of hydrogen bond donors (expressed as the sum of OHs and NHs).
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potency (compound 5), while the presence of NH increases
the potency of inhibition (compound 6). Further comparison of
compounds 1 and 3, which are also differ due to the values of X,
gave a similar result. Thus, the compound 1 (X=O) is more
active than that of compound 3. This is also supported by our
QSAR 6, which suggests that the activity of the molecules (VI)
will decrease by increasing their hydrophobicity.
The Clog P of these compounds is in the following order:
Compound 2 < Compound 5 > Compound 6
Similarly, compound 1<compound 3 (see Table 6).
Inhibition of HRV-2 by 3-X-5-Y-phenylisoxazoles (I) (Diana
et al., 1989) (Table 1).
From the data in Table 1, Eq. (7) was derived.
log1=MIC ¼ 10:37ðF2:96ÞClogP
 1:09ðF0:33ÞClogP2  17:23ðF6:51Þ ð7Þ
n=10, r2=0.940, s=0.199, q2=0.820, Q=4.874, F=54.833.
Range in log 1/MIC=5.21 to 7.70.
Optimum Clog P=4.77(4.66–4.95).
Outlier: X=Y=H.
Correlation matrix for Clog P vs. MW, CMR, MgVol, and
NVE: r2 <0.5.
It is a parabolic correlation in terms of Clog P, which
suggests that the inhibitory activities of 3-X-5-Y-phenylisox-
azoles (I) against HRV-2 first increases with an increase in
hydrophobicity up to an optimum Clog P of 4.77 and then
decreases. It means that the activity increases with the increase
in hydrophobicity of the molecules up to 4.77 (expressing the
first half of the parabolic relation) and decreases when
hydrophobicity is more than 4.77 (expressing the second half
of the parabolic relation).
In the case of QSAR 6, which is from a small data set and has
Clog P more than 4.77 for all the compounds (except one;
compound no.1), thus the decrease in activity of the molecules
(VI) with increase in their hydrophobicity should be expected.
We believe that QSAR 6 follows the same mechanism as of
QSAR 7 but partially that is the second half of the parabolic
relation. This may be the reason that the activity of
pyridazinylpiperidinyl derivatives (VI) decreases with the
increase in their hydrophobicity. Some more pyridazinylpiper-
idinyl derivatives (VI) will be needed to define the parabolic
relation and the confirmation of their mechanism of action.
Parabolic correlation with the hydrophobic parameter (Eq.
(7)) is an interesting example, where the optimal hydro-
phobicity is well defined. We believe that this equation may
be the predictive model to narrow the synthetic challenges in
order to yield very specific HRV-2 inhibitors. On the basis of
this model, and keeping the hydrophobicity (≤4.77) as well
as the molecular weight (≤500) by varying the values of X
and Y we can predict at least eleven compounds (I-1 to I-11).
The predicted log 1/MIC and calculated hydrophobicity are
given in Table 7. It is interesting to note that the proposed
molecules (I-1 to I-11) fulfill all conditions of the “rule of
five” (Table 7).In the process of drug discovery and development, the esti-
mation of molecular transport properties, particularly intestinal
absorption and blood–brain barrier penetration is one of the
important key factors. Traditionally, calculated values of n-
octanol/water partition coefficient have been used for this purpose
(Freitas, 2006). A set of rules, which imposes the limitations on
log P, molecular weight, and the number of hydrogen bond
donors and acceptors is known as “rule of five” and was
introduced by Lipinski et al. (1997). According to Lipinski's “rule
of five”, drug-like molecules should have log P≤5; molecular
weight ≤500; number of hydrogen bond acceptors (expressed as
the sum ofNs andOs)≤10; and number of hydrogen bond donors
(expressed as the sum of OHs and NHs)≤5. Molecules violating
more than one of these rules may have problems with
bioavailability. As an alternative to Lipinski rules, polar surface
area or VolSurf parameters can be used to predict oral absorption
and blood–brain barrier penetration (Kubinyi, 2003).
Inhibition of HRV-9 by 3,4-dihydro-2-phenyl-2H-pyrano
[2,3-b]pyridines (II) (Bargar et al., 1986) (Table 2).
QSAR 8 was developed from the data given in Table 2.
log1=ID50 ¼ 14:13ðF4:53ÞCMR 0:83ðF0:27ÞCMR2
 53:23ðF19:05Þ ð8Þ
n=10, r2=0.886, s=0.281, q2=0.697, Q=3.352, F=27.202.
Range in log 1/ID50=5.20 to 7.52.
Optimum CMR=8.53(8.37–8.69).
Outlier: X=Br, Y=4-Cl; X=SO2CH3, Y=4-Cl.
Correlation matrix for CMR vs. σX, and Clog P: r
2 <0.5.
The most important term is the molar refractivity of the
whole molecule for this data set. QSAR Eq. (8) is a parabolic
correlation in terms of CMR (calculated molar refractivity),
which suggests that the inhibitory activities of 3,4-dihydro-2-
phenyl-2H-pyrano[2,3-b]pyridines (II) against HRV-9 first
increases with an increase in molar refractivity up to an
optimum CMR of 8.53 and then decreases. CMR is primarily a
measure of bulk and of polarizability of the molecule. It means
that the bulk of the whole molecule plays a special role in
increasing the inhibitory potency. With respect to QSAR 8,
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(r=0.422). No role for a hydrophobic effect was found, which
contradicts QSAR 2.
Inhibition of HRV-14 by 3-X-5-Y-phenylisoxazoles (I) (Diana
et al., 1989) (Table 1).
From the data in Table 1, we derived Eq. (9).
log1=MIC ¼ 0:40ðF0:15ÞClogP  2:59ðF0:83ÞMgVol
 10:83ðF2:09Þ ð9Þ
n=9, r2=0.927, s=0.122, q2=0.865, Q=7.893, F=38.096.
Range in log 1/MIC=4.80 to 6.15.
Outliers: X=NO2, Y=Br; X=NO2, Y=Cl.
Correlation matrix for Clog P vs. MW, CMR, MgVol, and
NVE: r2 <0.5.
The major conclusions to be drawn from the above QSAR
are that hydrophobicity of 3-X-5-Y-phenylisoxazoles (I) pro-
motes their inhibitory activity towards HRV-14. MgVol is the
McGowan's volume (Abraham and McGowan, 1987), and its
negative coefficient indicates an unfavorable steric effect. With
respect to QSAR 9, there is not a significant correlation between
Clog P and MgVol (r=0.352).
Inhibition of HRV-21 by 3-X-5-Y-phenylisoxazoles (I).
(Diana et al., 1989) (Table 8).
From the data in Table 8, Eq. (10) was derived.
log1=MIC ¼ 1:70ðF0:69Þrm þ 5:99ðF0:52Þ ð10Þ
n=9, r2=0.830, s=0.293, q2=0.749, Q=3.109, F=34.176.
Range in log 1/MIC=5.92 to 7.70.
Outliers: X=CH3, Y=CH3; X=Cl, Y=CH3.
Clog P vs. σm: r=0.472.
Correlation matrix for σm vs. Clog P, CMR, MgVol, and
NVE: r2 <0.5.
The most important term is σm as an electronic descriptor
(sum of the σ values of X and Y substituents) for this data
set. Positive coefficient of σm indicates that electron with-
drawing X- and Y-group may enhance the inhibitory potency
of the molecules. No evidence for hydrophobic effect has been
found.Table 8
Biological and physicochemical parameters used to derive QSAR Eqs. (10) and
(11) for the inhibition of HRV-21 and HRV-22 by 3-X-5-Y-phenylisoxazoles (I)
No. X Y Log1/MIC (Eq. (11)) Log1/MIC (Eq. (11)) σm
Obsd. Pred. Δ Obsd. Pred. Δ
1 H H 5.92 5.99 −0.07 6.05 6.03 0.02 0.00
2 CH3 CH3 7.15
a 5.75 1.40 5.92 5.80 0.12 −0.14
3 Cl Cl 7.70 7.24 0.46 7.70 7.28 0.42 0.74
4 Br Br 7.40 7.31 0.09 7.30 7.34 −0.04 0.78
5 F F 6.92 7.14 −0.22 6.37 b 7.17 −0.80 0.68
6 Cl CF3 7.30 7.35 −0.05 7.40 7.38 0.02 0.80
7 Cl Br 7.70 7.28 0.42 7.30 7.31 −0.01 0.76
8 NO2 Br 7.52 7.85 −0.33 7.70 7.88 −0.18 1.10
9 NO2 Cl 7.70 7.82 −0.12 7.10 b 7.85 −0.75 1.08
10 Cl CH3 7.22
a 6.50 0.72 6.70 6.54 0.16 0.30
11 OCH3 OCH3 6.22 6.40 −0.18 5.92 6.44 −0.52 0.24
a Not included in the derivation of QSAR (10).
b Not included in the derivation of QSAR (11).Inhibition of HRV-22 by 3-X-5-Y-phenylisoxazoles (I) (Diana
et al., 1989) (Table 8).
From the data in Table 8, Eq. (11) was derived.
log1=MIC ¼ 1:68ðF0:54Þrm þ 6:03ðF0:35Þ ð11Þ
n=9, r2=0.885, s=0.273, q2=0.826, Q=3.447, F=53.869.
Range in log 1/MIC=5.92 to 7.70.
Outliers: X=Y=F; X=NO2, Y=Cl.
Clog P vs. σm: r=0.405.
Correlation matrix for σm vs. Clog P, CMR, MgVol, and
NVE: r2 <0.5.
QSAR Eq. (11) is very similar to that of 10 expressing the
similar mechanism.
Inhibition of HRV-25 by 3-X-5-Y-phenylisoxazoles (I) (Diana
et al., 1989) (Table 9).
From the data in Table 9, Eq. (12) was derived.
log1=MIC ¼ 0:78ðF0:29ÞClogP þ 2:37ðF1:41Þ ð12Þ
n=9, r2=0.850, s=0.259, q2=0.766, Q=3.560, F=39.667.
Range in log 1/MIC=4.87 to 6.70.
Outlier: X = NO2, Y=Cl.
Correlation matrix for Clog P vs. σm, MW, CMR, MgVol,
and NVE: r2 <0.5.
Positive Clog P suggests that highly hydrophobic 3-X-5-
Y-phenylisoxazoles (I) would be more active.
Inhibition of HRV-64 by 3,4-dihydro-2-phenyl-2H-pyrano
[2,3-b]pyridines (II) (Bargar et al., 1986) (Table 2).
QSAR 13 was developed from the data given in Table 2.
log1=ID50 ¼ 17:85ðF5:90ÞCMR 1:04ðF0:35ÞCMR2
 68:82ðF24:96Þ ð13Þ
n=10, r2=0.881, s=0.356, q2=0.689, Q=2.638, F=25.912.
Range in log 1/ID50=5.45 to 8.05.
Optimum CMR=8.60(8.44–8.78).
Outlier: X=Cl, Y=4-Cl; X=SO2CH3, Y=4-Cl.
Clog P vs. CMR: r=0.421.
Correlation matrix for CMR vs. σX, and Clog P: r
2 <0.5.
QSAR Eq. (13) is very similar to that of 8 suggesting the
similar kind of mechanism.
Inhibition of HRV-89 by 3-X-5-Y-phenylisoxazoles (I) (Diana
et al., 1989) (Table 9).
From the data in Table 9, Eq. (14) was derived.
log1=MIC ¼ 0:94ðF0:32ÞClogP þ 2:61ðF1:53Þ ð14Þ
n=9, r2=0.874, s=0.299, q2=0.712, Q=3.127, F=48.556.
Range in log 1/MIC=5.34 to 7.70.
Outliers: X=NO2, Y = Br; X=NO2, Y=Cl.
Again we obtained a positive contribution of hydrophobicity
as similar to QSAR 12.
Correlation matrix for Clog P vs. σm, MW, CMR, MgVol,
and NVE: r2 <0.5.
QSAR model validation
QSAR model validation is an essential task to develop a
statistically valid and predictive model, because the real utility of
Table 9
Biological and physicochemical parameters used to derive QSAR Eqs. (12) and
(14) for the inhibition of HRV-25 and HRV-89 by 3-X-5-Y-phenylisoxazoles (I)
No. X Y Log1/MIC (Eq. (12)) Log1/MIC (Eq. (14)) Clog
P
Obsd. Pred. Δ Obsd. Pred. Δ
1 H H – 5.43 – 6.40 6.30 0.10 3.91
2 CH3 CH3 6.15 6.21 −0.06 7.30 7.24 0.06 4.91
3 Cl Cl 6.52 6.33 0.19 7.70 7.39 0.31 5.07
4 Br Br 6.52 6.57 −0.05 7.70 7.67 0.03 5.37
5 F F 5.18 5.49 −0.31 6.70 6.37 0.33 3.99
6 Cl CF3 6.52 6.73 −0.21 7.40 7.87 −0.47 5.57
7 Cl Br 6.52 6.45 0.07 7.70 7.53 0.17 5.22
8 NO2 Br 6.30 5.78 0.52 7.52
a 6.72 0.80 4.36
9 NO2 Cl 6.70
b 5.66 1.04 7.70 a 6.58 1.12 4.21
10 Cl CH3 6.22 6.31 −0.09 7.22 7.36 −0.14 5.04
11 OCH3 OCH3 4.87 4.95 −0.08 5.34 5.72 −0.38 3.30
a Not included in the derivation of QSAR (14).
b Not included in the derivation of QSAR (12).
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property for new compounds. A comparison of the statistics of
QSAR (1)–(14) obtained frommulti-regression analyses (MRA)
have been shown in Table 10. All the QSAR are found to be
statistically significant. The following approaches have been
used for the validation of QSAR (1)–(14):
• Fraction of the variance: It is important to note that a
QSAR model must have to explain a sufficiently highTable 10
Summary of critical variables in QSAR Eqs. ((1)–(14)) on HRV inhibitors
QSAR
No.
HRV
Type
Compounds n r2 s q2 Q
1 1A 3-X-5-Y-phenylisoxazoles (I) 11 0.898 0.133 0.853 7.128
2 1A 3,4-dihydro-2-phenyl-2H-
pyrano[2,3-b] pyridines (II)
11 0.806 0.249 0.727 3.606
3 1B 2-X-6-(dimethylamino)-9-
(4-methylbenzyl)-9H-
purines (III)
10 0.925 0.298 0.898 3.228
4 1B 2-X-6-(dimethylamino)-9-
(Y-benzyl)-9H-purines (IV)
29 0.893 0.334 0.848 2.829
5 2 2-(X-phenoxy)-5-
nitrobenzonitries (V)
20 0.833 0.280 0.776 3.261
6 2 Pyridazinylpiperidinyl
derivatives (VI)
5 0.975 0.043 0.895 22.953
7 2 3-X-5-Y-phenylisoxazoles (I) 10 0.940 0.199 0.820 4.874
8 9 3,4-dihydro-2-phenyl-2H-
pyrano[2,3-b] pyridines (II)
10 0.886 0.281 0.697 3.352
9 14 3-X-5-Y-phenylisoxazoles (I) 9 0.927 0.122 0.865 7.893
10 21 3-X-5-Y-phenylisoxazoles (I) 9 0.830 0.293 0.749 3.109
11 22 3-X-5-Y-phenylisoxazoles (I) 9 0.885 0.273 0.826 3.447
12 25 3-X-5-Y-phenylisoxazoles (I) 9 0.850 0.259 0.766 3.560
13 64 3,4-dihydro-2-phenyl-2H-
pyrano[2,3-b] pyridines (II)
10 0.881 0.356 0.689 2.638
14 89 3-X-5-Y-phenylisoxazoles (I) 9 0.874 0.299 0.712 3.127
a Clog P(o)=optimum value of Clog P.
b CMR(o)=optimum value of CMR.fraction of the variance for any data set. The fraction of the
variance of an MRA model is expressed by r2 (measure of
the goodness of fit between model-predicted and experi-
mental values). It is believed that the closer the value of r2
to unity, the better the QSAR model. The values of r2 for
QSAR models (1)–(14) are 0.806 to 0.975 (Table 10). The
high values of r2 confirmed that the high fraction of the
variance (80.6–97.5%) has been explained by these QSAR
models.
• Cross-validation test: The cross-validated correlation coeffi-
cient (q2) was obtained by using the leave-one-out procedure
(Cramer et al., 1988). The values of q2 for QSAR models
(1)–(14) are 0.689 to 0.898 (Table 10). The high values of q2
validate these QSAR models. In the literature, it must be
greater than 0.50 (Golbraikh and Tropsha, 2002).
• Standard deviation (s): s is the standard deviation about the
regression line. This is a measure of how well the function
derived by the QSAR analysis predicts the observed
biological activity. The smaller the value of s the better the
QSAR model. The values of s for QSAR models (1)–(14)
are 0.043 to 0.356 (Table 10).
• Quality factor or quality ratio (Q): Chance correlation, due
to the excessive number of parameter (which increases also
the r and s values) is detected by the examination of Q
value (Pogliani, 1996, 2000; Agrawal et al., 2006). The
values of Q for QSAR models (1)–(14) are 2.638 to 22.953
(Table 10). The high values of Q showed the highF Descriptor coefficients Intercept
Hydrophobic a Steric b Electronic Others
79.235 0.52 Clog P – – – 3.10
37.392 0.58 Clog P – – – 4.24
98.667 1.11 πX – – – 5.78
69.548 0.41 πY−3 1.06 B1Y− 4 – 1.51IX 3.38
89.784 0.79 Clog P – – – 2.63
117.000 −0.49 Clog P – – – 9.47
54.833 10.37 Clog P–
1.09 Clog P2
Clog P(o)=4.77
– – – −17.23
27.202 – 14.13 CMR
−0.83 CMR2
CMR(o)=8.53
– – −53.23
38.096 0.40 Clog P −2.59 MgVol – – −10.83
34.176 – – σm – 5.99
53.869 – – σm – 6.03
39.667 0.78 Clog P – – – 2.37
25.912 – 17.85 CMR
−1.04 CMR2
CMR(o)=8.60
– – −68.82
48.556 0.94 Clog P – – – 2.61
160 R.P. Verma, C. Hansch / Virology 359 (2007) 152–161predictive power of the QSAR models and also no over
fitting.
• Fischer statistics (F): Fischer statistics (F) is a value derived
from F-test indicating the probability of a true relationship,
or the significance level of the MLR model. The F-value is
the ratio between explained and unexplained variance for a
given number of degree of freedom. The larger the F-value
the greater the probability that the QSAR equation is
significant. The F-values obtained in QSAR models (1)–
(14) are 25.912 to 117.000 (Table 10) and statistically
significant at 95% level.
All the QSAR models (except QSAR 9, which has nine data
points against two descriptors) also fulfill the thumb rule
condition that is (number of data points)/(number of descrip-
tors) ≥5.
Conclusion
An analysis of our QSAR results on the inhibition of various
six compound series against HRV-1A, -1B, -2, -9, -14, -21, -22,
-25, -64, and -89 reveals a number of interesting points. The
most important of these is hydrophobicity, which is one of the
most important determinants of activity. Out of 14 QSAR, 10
contain a correlation between activity and hydrophobicity. A
positive linear correlation is found in 8 equations (Eqs. (1–5),
(9), (12), and (14)). The coefficient with the hydrophobic
parameter varies considerably, from a low value of 0.40 (Eq.
(9)) to the high value of 1.11 (Eq. (3)). These data suggest that
activity might be improved by increasing compound/substituent
hydrophobicity. A negative linear correlation is found in only
one equation (Eq. (6)), and the coefficient is −0.49. Less
hydrophobic congeners in this compound family might display
enhanced activity. Parabolic correlation with hydrophobicity is
also found in one equation (Eq. (7)). This may be an
encouraging example, where the optimal hydrophobicity is
well defined that is log P(o) = 4.77. We believe that this may be
the predictive model to narrow the synthetic challenges in order
to yield very specific HRV-2 inhibitors. On the basis of this
model, we can predict eleven compounds I-1 to I-11 (Table 7).
It is interesting to note that the proposed molecules (I-1 to I-11)
fulfill all the conditions of Lipinski's “rule of five”.
The second important parameter is molar refractivity, which
is present in two QSAR. Other parameters, sterimol, molar
volume, and electronic also appear in several QSAR. In some
cases, these parameters correlate all of the observed variation in
activity, but they do not seem to play as important a role as
hydrophobicity for the data sets that we have examined.
Materials and methods
All the data have been collected from the literature (see
individual QSAR for respective references). IC50, ID50, and
EC50 are the 50% inhibitory concentration of a compound and
expressed in molar concentration. Similarly, MIC is the
minimum inhibitory concentration of a compound in molar
concentration, whereas MIC50 is the minimum inhibitoryconcentration: the molar concentration of compound to reduce
the viral cytopathic effect by 50% compared to control. Log 1/
IC50, log 1/ID50, log 1/EC50, log 1/MIC, and log 1/MIC50 are
the dependent variables, which define the biological parameter
for QSAR equations. Physicochemical descriptors are auto-
loaded, and multi-regression analyses (MRA) used to derive the
QSAR are executed with the C-QSAR program (http://www.
biobyte.com). Selection of descriptors is made on the basis of
permutation and correlation matrix among the descriptors (to
avoid collinearity problems). The details about the C-QSAR
program, the search engine, the choice of parameters and their
use in the development of QSAR models, have already been
discussed (Hansch et al., 2002). The parameters used in this
paper have also been discussed in detail along with their
application (Hansch and Leo, 1995). Briefly, Clog P is the
calculated partition coefficient in n-octanol/water and is a
measure of hydrophobicity, and π is the hydrophobic parameter
for substituents. σ, σ+ and σ− are Hammett electronic
parameters that apply to substituent effects on aromatic systems.
B1, B5 and L are Verloop's sterimol parameters for substituents
(Verloop, 1987). B1 is a measure of the width of the first atom
of a substituent, B5 is an attempt to define width of the whole
substituent and L is the substituent length.
CMR is the calculated molar refractivity for the whole
molecule. MR is calculated from the Lorentz–Lorenz equation
and is described as follows: [(n2−1)/(n2 +2)](MW/δ), where n
is the refractive index, MW is the molecular weight, and δ is the
density of the substance. MR is dependent on volume and
polarizability. It can be used for a substituent or for the whole
molecule. A new polarizability parameter, NVE, was devel-
oped, which is shown to be effective at delineating various
chemico-biological interactions (Hansch and Kurup, 2003;
Hansch et al., 2003; Verma and Hansch, 2005; Verma et al.,
2005a, 2005b). NVE represents the total number of valence
electrons and is calculated by simply summing up the valence
electrons in a molecule, that is, H=1, C=4, Si=4, N=5, P=5,
O=6, S=6 and halogens=7. It may also be represented as:
NVE=nσ+nπ+nn, where nσ is the number of electrons in σ-
orbital, nπ is the number of electrons in π-orbitals, and nn is the
number of lone pair electrons. MgVol is the molar volume for
the whole molecule (Abraham and McGowan, 1987). The
indicator variable I is assigned the value of 1 or 0 for special
features with special effects that cannot be parameterized and
has been explained wherever used.
In QSAR equations, n is the number of data points, r is the
correlation coefficient between observed values of the depen-
dent and the values calculated from the equation, r2 is the
square of the correlation coefficient represents the goodness of
fit, q2 is the cross-validated r2 (a measure of the quality of the
QSAR model), and s is the standard deviation. The cross-
validated r2 (q2) is obtained by using leave-one-out (LOO)
procedure (Cramer et al., 1988). Q is the quality factor (quality
ratio), where Q= r/s. Chance correlation, due to the excessive
number of parameter (which increases the r and s values also),
can, thus, be detected by the examination of Q value. F is the
Fischer statistics (Fischer ratio), F= fr2/[(1− r2)m], where f is
the number of freedom, f=n− (m+1), n=number of data
161R.P. Verma, C. Hansch / Virology 359 (2007) 152–161points, and m=number of variables. The modeling was taken to
be optimal when Q reached a maximum together with F, even if
slightly non-optional F values have normally been accepted. A
significant decrease in F with the introduction of one additional
variable (with increasing Q and decreasing s) could mean that
the new descriptor is not as good as expected, that is, its
introduction has endangered the statistical quality of the
combination that nevertheless can again improve with the
ulterior introduction of a more convincing descriptor (Pogliani,
1996, 2000; Agrawal et al., 2006). Compounds were assigned to
be outliers on the basis of their deviation between observed and
calculated activities from the equation (>2s) (Selassie et al.,
2005; Verma and Hansch, 2006). Each regression equation
includes 95% confidence limits for each term in parentheses.
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